
PolyPid (PYPD) Stock Forecast & Price Target
PolyPid (PYPD) Analyst Ratings
Bulls say
PolyPid is well-positioned for success with a proven drug delivery technology, a strong pipeline of products, and a strategic partnership with Azurity Pharmaceuticals to support commercialization efforts. The company has also secured a significant amount of upfront and near-term payments, as well as potential milestone payments, which reduces financing risk and provides runway into profitability in 2029. With a strong management team and major advancements on the regulatory and commercial fronts, PolyPid has the potential to drive significant value for its shareholders in the long term.
Bears say
PolyPid is overvalued as a single asset company with a current market value of $177 million, given that their sole product candidate D-PLEX100 is still in clinical stages and faces competition in the anti-infective market. Although the company may receive significant upfront and milestone payments, their tiered royalty structure may not generate significant revenue in the near term and the success of their broader pipeline approach remains uncertain. Additionally, the company's financial stability may be at risk if they are unable to secure a commercial partnership for D-PLEX100.
This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.
PolyPid (PYPD) Analyst Forecast & Price Prediction
Start investing in PolyPid (PYPD)
Order type
Buy in
Order amount
Est. shares
0 shares